Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers

Medical and Pediatric Oncology

Volumn 40, Issue 6, 2003, Pages 343-347

  Gupta, Monesha ^a,b   Steinherz, Peter G ^a   Cheung, Nai Kong ^a   Steinherz, Laurel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anthracyclines; Cardiotoxicity; Shortening fraction

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HODGKIN DISEASE; HUMAN; MALE; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASMS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037410353     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10298     Document Type: Article

References (20)

1. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
2. Ewer MS, Jaffe N, Ried H, et al. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med Pediatr Oncol 1998;31:512-515.
3. Speyer JL, Green MD, Dubin N, et al. Prospective evaluation of cardiotoxicity during a 6-hr doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med 1985;78:555-563.
4. Hortobagyi GN, Frye RN, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989;63:37-45.
5. Legha SS, Benjamin RS, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982;49:1762-1766.
6. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-139.
7. Casper ES, Gaynour JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68:1221-1229.
8. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hr infusion regimen. A prospective randomized evaluation. Cancer 1990;65:870-873.
9. Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: effect of different schedules on toxicity and antitumour efficacy. Eur J Cancer Clin Oncol 1989;25:873-882.
10. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group Study. J Natl Cancer Institute 1991;83:926-932.
11. Steinherz PG, Redner A, Steinherz L, et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. Cancer 1993;72:3120-3130.
12. Steinherz LJ, Steinherz PG, Heller G. Cardiac toxicity after treatment for childhood cancer, Chapter 7. In: Anthracycline-related cardiac damage. New York: Wiley-Liss, Inc.; 1993. p 63-72.
13. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the children's cancer study group. Pediatrics 1992;89:942-948.
14. Feigenbaum H. Echocardiographic measurementss and normal values. Appendix, Echocardiography, 3rd Edition. Philadelphia, PA: Lea & Febiger; 1981. p 549-563.
15. Greene RF, Collins JM, Jenkins JF, et al. Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983;43:3417-3421.
16. Samuel L, Cummings J, Shaw P. Daunarubicin cardiotoxicity in childhood cancer. Lancet 1998;352:1150.
17. Kakadekar AP, Sandor GG, Fryer C, et al. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Med Pediatr Oncol 1997;28:22-26.
18. Lipschultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002;20:1677-1682.
19. Von-Hoff DD, Rozenweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9(1):23-33.
20. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983;43:4467-4469.